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MODELING THE WOUND HEALING IN NECROTIZING ENTEROCOLITIS  
AND DIABETIC FOOT ULCER  
 
Qi Mi, PhD 
University of Pittsburgh, 2007
 
      In my thesis, I present three different models for the wound healing in Necrotizing 
Enterocolitis and Diabetic Foot Ulcer. (I) NEC results after an injury to the mucosal 
lining of the intestine, leading to translocation of bacteria and endotoxin. Intestinal 
mucosal defects are repaired by the process of intestinal restitution, during which 
enterocytes migrate from healthy areas to sites of injury. To model the migration of 
enterocytes, first we formulate a one-dimensional mathematical model based on the 
assumption of elastic deformation of the cell layer. Then we extend the model into a two-
dimension space and the resulting moving boundary problem is solved by using modified 
Finite Element Method.  (II) Diabetic foot ulcers (DFU) are caused by both vascular and 
neurologic complications of diabetes, in combination with persistent opportunistic 
infections and deficient wound healing. We develop an Agent-based computational 
model to simulate its inflammation and the resolution of the inflammatory response in its 
wound healing process.  
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1.0  INTRODUCTION 
1.1 NECROTIZING ENTEROCOLITIS 
Necrotizing enterocolitis (NEC) is the leading cause of death from gastrointestinal 
disease in preterm infants. "Necrotizing" means damage and death of cells; "entero" refers to the 
intestine; "colitis" means inflammation of the colon (lower part of the intestine).  With mortality 
rates approaching 50% in infants who weigh less than 1500 g, NEC represents a significant 
clinical problem. Although, it is more common in premature infants, it can also be observed in 
term babies. It results from an injury to the mucosal lining of the intestine, leading to 
translocation of bacteria and endotoxin into the circulation. Intestinal mucosal defects are 
repaired by the process of intestinal restitution, during which enterocytes migrate from healthy 
areas to sites of injury.  
In my thesis, first we develop a mathematical model of migration of enterocytes during 
experimental NEC in one-dimensional space (35). The model is based on a novel assumption of 
elastic deformation of the cell layer and incorporates the following effects (i) mobility promoting 
force due to lamellipod formation, (ii) mobility impeding adhesion to the cell matrix, and (iii) 
enterocyte proliferation. Our model successfully reproduces the behavior observed for enterocyte 
migration on glass coverslips, namely the dependence of migration speed on the distance from 
the wound edge, and the finite propagation distance in the absence of proliferation which results 
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in an occasional failure to close the wound. It also qualitatively reproduces the dependence of 
migration speed on integrin concentration. The model is applicable to the closure of a wound 
with a linear edge and, after calibration with experimental data, could be used to predict the 
effect of chemical agents on mobility, adhesion, and proliferation of enterocytes.  Secondly to 
model a more general scenario, we derive a two-dimensional partial-differential model based on 
the laws of continuum mechanics and it is analogous to Darcy’s law in the theory of flow 
through porous media. The resulting moving-boundary problem is numerically solved by using 
modified finite element method. Although for the current model, we only consider the case for 
the absence of proliferation, like our 1d model, it also successfully reproduces the behavior 
observed for enterocytes migration.  
 
     
 
1.2 DIABETIC FOOT ULCER 
Inflammation and wound healing are inextricably linked and complex processes, and are 
deranged in the setting of chronic, non-healing diabetic foot ulcers (DFU). An ideal therapy for 
DFU should both suppress excessive inflammation while enhancing healing. We reasoned that 
biological simulation would clarify mechanisms and help refine therapeutic approaches to DFU. 
We developed an agent-based model (ABM) capable of reproducing qualitatively much of the 
literature data on skin wound healing, including changes in relevant cell populations 
(macrophages, neutrophils, fibroblasts) and their key effector cytokines (tumor necrosis factor-α 
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[TNF], interleukin [IL]-1β, IL-10, and transforming growth factor-β1 [TGF-β1]) (62). In this 
simulation, a normal healing response results in tissue damage that first increases (due to wound-
induced inflammation) and then decreases as collagen levels increase. Studies by others suggest 
that diabetes and DFU are characterized by elevated TNF and reduced TGF-β1, though which of 
these changes is a cause and which one is an effect is unclear. Accordingly, we simulated the 
genesis of DFU in two ways, either by 1) increasing the rate of TNF production fourfold, or 2) 
by decreasing the rate of TGF-β1 production 67% based on prior literature. Both manipulations 
resulted in increased inflammation (elevated neutrophils, TNF, and tissue damage), and delayed 
healing (reduced TGF-β1 and collagen). Our ABM reproduced the therapeutic effect of PDGF/ 
platelet releasate treatment as well as DFU debridement. We next simulated the expected effect 
of administering 1) a neutralizing anti-TNF antibody, 2) an agent that would increase the 
activation of endogenous latent TGF-β1, or 3) latent TGF-β1 (which has a longer half-life than 
active TGF-β1), and found that these therapies would have similar effects regardless of the initial 
assumption of the derangement that underlies DFU (elevated TNF vs. reduced TGF-β1). 
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2.0   ONE-DIMENSIONAL ELASTIC CONTINUUM MODEL OF ENTEROCYTE 
LAYER MIGRATION 
In this chapter, I describe our one-dimensional elastic continuum model of enterocyte layer 
migration in necrotizing enterocolitis. 
2.1 INTRODUCTION 
The ability of the cells that line the surface of the intestine to move plays a critical role in 
the ability of the body to heal any injury to the intestinal lining. The process by which such cells 
– called enterocytes –move is of great scientific interest. For example, there are certain 
conditions in which enterocyte migration is inhibited, therefore rendering the body susceptible to 
further injury and illness. One such condition is termed necrotizing enterocolitis (NEC), a 
disease that affects young babies and is characterized by impairment in the ability of enterocytes 
to move effectively, resulting in impaired healing (1-5). Mucosal healing also requires the 
generation of new enterocytes from precursors that are located deep within crypts of the mucosal 
lining, a process termed enterocyte proliferation (6). Enterocyte proliferation takes days before 
new cells are generated, as compared to enterocyte migration which may be completed within 
hours. Accordingly, it has become apparent that mucosal healing is largely determined by 
enterocyte migration (7), at least during the early phases. An understanding of the mechanisms 
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that govern enterocyte migration is therefore of vital importance in order to gain insights into the 
regulation of intestinal physiology during conditions of both health and disease. Importantly, 
little information exists to characterize the factors that regulate enterocyte migration under 
conditions that are associated with intestinal inflammation such as occurs in NEC. 
Although many molecules may act in concert to inhibit enterocyte migration in the 
development of NEC, bacterial endotoxin (lipopolysaccharide, LPS) is likely to act as one of the 
earliest. LPS, which is found on the outer wall of gram negative bacteria, is a potent 
immunostimulant that exerts a large effect on the ability of enterocytes to migrate, given the 
large concentrations present within the lumen of the intestine. Mathematical modeling is 
emerging as an approach by which to address the complexity of inflammation in general (31) and 
of NEC in particular (30). To design experimental and mathematical models to predict the 
development of NEC, we therefore turned to an in vitro system in which small intestinal 
enterocytes (IEC-6 cells) were exposed to LPS at concentrations known to be present in the 
lumen of animals with experimental NEC (100ng/ml to 50µg/ml). The exposure of enterocytes to 
LPS in this concentration range leads to a profound, dose-dependent inhibition of enterocyte 
migration (8). Studies directed at elucidating the mechanisms that could mediate this migration 
inhibitory effect showed that LPS increases the adhesion of cells to the underlying matrix.  This 
increased adhesion occurred due to a profound increase in the number of attachment sites – 
termed focal adhesions (8) – as well as an increase in the expression of binding receptors – called 
integrins – on the surface of the cell (9), in response to LPS.   
The primary motivation for development of the model described herein is that the ability 
to predict the effect[s] of LPS and integrins on migration of enterocytes could have tremendous 
significance in understanding, and perhaps correcting, the factors leading to the defect in 
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mucosal healing that characterizes NEC. We give a mathematical description of the moving 
enterocyte layer and describe its properties by three constants related to the adhesion of cells to 
substrate, the elasticity of the layer, and the force exerted by lamellipodia, which are foot-like 
projections from the cell surface that allow the cell to move forward.  We calibrate our model 
with real-time observations of cell migration and obtain estimates of these parameters. Finally, 
we find that with natural assumptions regarding the dependence of adhesion and lamellipod force 
on integrin concentration, the model yields results that are in qualitative agreement with 
experimental observations of the effect of adhesion on cell migration speed (10, 11). 
 
2.2 THEORY AND METHODS 
Existing mathematical models of wound healing are generally based on reaction-diffusion 
formalism in which moving edge of the cell layer is represented as a traveling wave of cell 
concentration. For adult epidermal wound healing, Sherratt and Murray (12) proposed a two-
component model in which the epithelial layer is described by giving cell density per unit area 
and the time-dependence of this density is related to the concentration of the mitosis-regulating 
chemical. For embryonic epidermal wound healing Sherratt (13) developed a model involving 
actin filament network formation, based on a mechanochemical model for the deformation of 
epithelial sheets proposed by Murray and Oster (14). Recently Walker et al. (15, 16) used an 
agent-based model to simulate the wounded epithelial cell monolayers and suggested that simple 
rules are sufficient to qualitatively predict the calcium-dependent pattern of wound closure 
observed in vitro. In dermal wound healing, the mathematical model derived by Tranquillo and 
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Murray (17) includes the mechanism of dermal wound contraction.  More complicated models 
including multiple cell types and multiple types or phases of the viscoelastic extracellular matrix 
(ECM) have been developed, some including additional equations for chemicals (such as growth 
factors) which modulate cell proliferative, motile and contractile behavior (18, 19). A detailed 
model of the dependence of cell speed on adhesion-receptor/ligand binding was proposed by 
DiMilla et al. (20).   
In the present chapter, we focus on modeling the natural, unimpeded, cell migration 
during healing of the damaged intestinal mucosa. To design experimental and mathematical 
models to predict the development of the migration defect that characterizes NEC, the 
researchers in Dr. David Hackam’s lab in University of Pittsburgh utilized a system in which 
small intestinal enterocytes (IEC-6 cells) are cultured on a glass coverslip, grown to confluence, 
and then scraped with a pipette or cell scraper to create a gap that represents the wound.  The 
cells undergo motion, deformation, and proliferation. They have observed that the enterocyte cell 
layer is only one cell deep, and that during migration cells do not separate from the edge and no 
holes are formed in the interior of the layer. In addition, during migration cells at the edge and in 
the interior of the layer move generally toward the wound and never away from it (see Figure 2-
4). Therefore, instead of a collection of diffusing cells, the cell layer can be described as an 
elastic continuum in which cells are connected, albeit loosely, to each other.  The cells appear to 
move in accord with the so called 'sliding mechanism', in which cells in the interior respond 
passively to the pull of the cells at the edge (32,33,34).  
 7 
2.3 MATHEMATICAL FORMULATION 
The motion of cells is assumed to be driven by the cells at the edge of the wound through 
the formation of lamellipodia, which produce the driving force (22). The cells in the interior do 
not form lamellipodia and hence are not directly actuating the motion. However, they are tightly 
connected to the cells at the boundary. Tight junctions between the cells prevent separation (23) 
and hence the edge cells pull with them the cells in the interior of the layer.  The cell layer 
stretches because of the tension applied by the edge cells, and the motion of the cells is slowed 
down by the adhesion between cells and the substrate. 
The cell layer is represented by a one-dimensional elastic continuum capable of 
deformation, motion, and material growth (see Figure 2-1). Initially, the continuum is uniform 
and free from internal stresses. After part of the layer is scraped, a net external force F acting on 
the layer will develop at the resulting boundary as a result of lamellipod formation. This force, 
which will cause the layer to move and deform, will be opposed by the tension in the continuum 
resulting from stretching of the cells in the layer, and also by the adhesion between the 
continuum and the substrate during the motion. 
Our model differs from published viscoelastic continuum models of epithelial sheets (17) 
in that we ascribe elasticity to the cell layer itself, but not to the substrate matrix. The forces 
considered in (17) are elastic forces and traction forces arising from the actin filament network 
between the cells and substrate that attaches to the cells. In our model, because we are concerned 
with in vitro experiments in which IEC-6 cells are planted on glass coverslips, we can safely 
ignore the elasticity of the substratum and only consider the forces coming from the lamellipod 
of the cells at edge and interaction between cells.  
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Figure 2-1: (A) Sketch of the experimental setup for monitoring in vitro mobility. Confluent IEC-6 cells were plated on glass 
coverslips, scraped with a cell scraper, and then mounted on the stage of an Olympus 1X71 inverted microscope warmed to 
37°C. Fresh medium was continuously perfused across the cells. Differential interference contrast images were obtained 
every 5 min. (B) Schematic representation of the cell layer as one-dimensional continuum (only one side of the wound is 
shown): (i) Initial state. (ii) Hypothetical state at time t accounting for growth but not deformation. (iii) True configuration of 
the layer at time t 
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            We employ the variable s to describe the position of a cell in the original layer. A 
proliferating cell generates two “offspring”.  We adhere to the convention that the offspring that 
is closer to the moving edge of the layer carries the s value of the original cell and we employ the 
variable  to denote the position of cell s in the layer at time t. In other 
words,
),( stx
t sx ≤≤ σσ 0),,
≤≤
(
s
, is the position at time t of the offspring of cells originally located 
between 0 and s. In addition, we introduce the variable  which describes the hypothetical 
position of cell s at time t if all deformation in the layer was instantaneously removed. Thus, 
),(ˆ sts
ts σσ 0),,(ˆ
dss +
, would be the position at t of the offspring of cells originally located between 0 
and s if we accounted for growth but not deformation (see Figure 2-1). 
Let us now consider a segment of cells which are the offspring of cells between s and 
 of the original layer with ds  assumed small.  At time t, such a segment extends between 
 and , its velocity is),( stx ),( dsstx + tstxstx ∂∂= ),(),(& , and acceleration 22 ),(),( tstxstx ∂∂=&& . 
Balance of momentum implies that 
                 ),(),(),(),(),(),( stfdsstfstxstBstxstM −+=+ &&&                          (2.1) 
where  is the time-dependent mass of the segment,  is the coefficient describing 
the sliding resistance due to adhesion of the cells to the substrate, and f the resultant force on a 
cross-section of the layer. 
),( stM ),( tsB
It is reasonable to assume that the coefficient  is proportional to the extent of 
contact of the segment with the substrate (10,11) and hence 
),( tsB
( )bstxdsstxtB ),(),()( −+=                                    (2.2) 
where b is the adhesion constant, which has the units of force times time divided by length 
squared. In addition, for slow motions one may neglect the acceleration term in Eq. 2.1 and 
hence, in view of Eq. 2.2, one obtains 
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( ) ),(),(),(),(),( stfdsstfstxbstxdsstx −+=−+ &              (2.3) 
which, in the limit , becomes, 0→ds
s
f
t
x
s
xb ∂
∂=∂
∂
∂
∂                                         (2.4) 
The strain (deformation gradient) in the cell layer can be described by the quantity 
1ˆ −∂∂= sxε , with 0>ε  corresponding to stretch and 01 <<− ε  corresponding to compression.  
The model must be completed by an appropriate choice of the constitutive relation describing the 
dependence of f on ε . When ε  is small, one could assume that the resultant force is a linear 
function of the strain (Hooke’s law): 
                           ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −⎟⎠
⎞⎜⎝
⎛
∂
∂
∂
∂==
−
1
ˆ 1
s
s
s
xkkf ε                                        (2.5) 
Here the stretching modulus of the layer k has the unit of force as the cell-layer thickness is 
assumed constant. The drawback of Eq. 2.5 is that the resultant force (and hence the strain) 
remains finite if the material is compressed to infinitesimal volume.  A more appropriate choice, 
which we make here, yields infinite magnitude of the resultant force for both 1−→ε  and 
∞→ε : 
                                ⎥⎦
⎤⎢⎣
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⎞⎜⎝
⎛
∂
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⎞⎜⎝
⎛
∂
∂=+=
s
s
s
xkkf
ˆ
lnln)1ln(ε                       (2.6) 
(The difference between Eq. 2.5 and Eq. 2.6 is exhibited only when the cell layer is subjected to 
extreme deformation.  We have verified that the choice of Eq. 2.5 instead of Eq. 2.6 would yield 
results essentially indistinguishable from those presented in this chapter.)   
Any deformation of a cell is accompanied by an active remodeling of the cytoskeleton 
which generally results in a viscoelastic stress-strain response (24). In Eqs. 2.5 and 2.6 it is 
implicitly assumed that the stretching modulus k of the cell layer is time independent and hence 
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the cell layer responds instantaneously and passively to the forces generated on it.  This 
assumption is made due to the fact  that the timescale of the motion of the layer (~hours) is slow 
compared to the relaxation time of single-cell deformation which is of the order of tens of 
seconds (25).   Therefore, one should think of k as the residual stretching modulus of the layer 
after cytoskeleton relaxation. 
Material growth and decay of the layer can be described using the growth gradient 
ssstg ∂∂= ˆ),( , which obeys 
                                             ),(),( stg
t
stg ρ=∂
∂                                         (2.7) 
where the growth rate ρ  may generally depend on s, t but also ε  or g itself. If one assumes that 
the growth rate is time and strain independent, the solution of Eq. 2.7 with initial condition 
 is easily obtained as 1),0( =sg
  .                                     (2.8) tsestg )(),( ρ=
From Eqs. 2.4, 2.6, 2.8 we obtain resulting equation: 
                                       ⎟⎟⎠
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⎞⎜⎝
⎛
∂
∂
∂
∂=∂
∂
∂
∂ ts
s
x
sb
k
t
x
s
x )(ln ρ                        (2.9) 
We assume that the location of the left boundary of the cell layer (at ) is fixed 
while the right boundary (at  in dimensionless units) is free to move, and that the force 
applied at the right boundary is constant and equal to F.  Thus, the initial and boundary 
conditions are, in view of Eq. 2.5, 
0=s
1=s
 
te
s
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ttx
sssx
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∂
≤=
≤≤=
+ 0,)1,(
0,0)0,(
10,),0(
)1()/( ρ
                     (2.10) 
Note that the constants b, k, and F appear in the problem only as the ratios bk /=κ  
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(units of length squared divided by time) and kF /=φ  (dimensionless).  The differential 
equation Eq. 2.9 with boundary and initial conditions Eqs. 2.10 can be solved numerically using 
finite difference methods (see Appendix A). 
 
2.4 CONSTANT GROWTH RATE 
        If the growth rate ρ  is spatially independent, the problem of Eqs. 2.9, 2.10 further simplifies 
as 
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                                (2.11) 
Figure 2-2 gives an example of the typical features of solutions of Eqs. 2.11 with a 
constant positive growth rate. The initial motion is dominated by the force applied by the 
lamellipodia on the edge of the layer.  The velocity of the edge is decreasing as a result of 
increasing tension and increasing adhesion in the extended layer. The cells in the interior of the 
layer remain static for a time period proportional to their distance from the edge. At later times 
the motion of the layer becomes dominated by cell proliferation and the velocity of the edge 
increases again. The tensile strain decreases and eventually becomes positive.  At this stage, the 
proliferation of new material, which pushes the old cells out of the way, is the driving force 
behind the motion of the layer. 
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Figure 2-2: Generic behavior at constant proliferation rate. Here 2.0=ρ , 1=κ , and 4.0=φ .  (A) Graphs of the position x of cells 
with s = 0.25, 0.5, 0.75, 1 as a function of time (in hours). (B) Resultant force f in the layer versus position s for t = 0, 2, 4, 6, 8 hr. 
(C) Velocity of the edge as a function of time (in hours). 
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 2.5 CALIBRATION IN THE ABSENCE OF PROLIFERATION 
In the case of migration of enterocytes on glass cover slips considered in this paper, we 
have observed that the proliferation rate is very low. In this case, ρ  can be neglected and the 
problem Eqs. 2.11 becomes 
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                    (2.12) 
The differential equation in Eq. 2.12 has an equilibrium (i.e., time-independent) solution 
 that obeys the prescribed boundary conditions (but not the initial condition).  This 
solution is a limiting case of the time-dependent solution and it implies that the maximum 
distance the right edge of the layer can reach is . 
sesx φ=)(
φex =max
 
2.6 RESULTS 
The parameters κ  and φ  of the model in Eq. 2.12 can be determined by calibration with 
experimental data obtained in vitro.  In the experiment described in (5), IEC-6 cells were grown 
on glass coverslips to 100% confluence, serum-starved for 12 hours, scraped with a cell scraper, 
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and then transferred to the stage. Pictures were taken every five minutes for 17 hours to record 
the migration profiles of the cells. Figure 2-3 shows examples of such pictures. We used the 
recorded pictures of migrating cells to track the motion of selected ten cells located near the 
edges and in the interior of the layer.  The cells are marked L1-L10 (in the lower layer) and U1-
U10 (in the upper layer) (see Fig. 2-4). The distance traveled by the cells was measured in the 
direction perpendicular to the axis of the wound. 
 
 
A B C 
 
 
 
 
 
 
Figure 2-3: Snapshots of IEC-6 cells migrating on a glass cover slip at (A) t = 0, (B) t = 5h and (C) t = 10h. The tracked 
cells are labeled as U1…U10 and L1…L10 Snapshots of IEC-6 cells migrating on a glass cover slip at (A) t = 0, (B) t = 
5h, and (C) t = 10h. The tracked cells are labeled as U1…U10 and L1…L10 
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Figure 2-4: The observed paths of cells U1…U10 and L1…L10 of Figure 3. The positions of edges at t = 0 are indicated 
by solid lines.  The direction of motion, along which traveled distances were measured, is shown as dash-dotted line.  
From these measurements, we fit the average position of the group of cells L1-L5 in the 
interior of the lower layer and the group of cells L6-L10 near the edge. The model parameters 
were estimated using numerical solution of Eq. 12 and a routine nonlinear unconstrained 
minimization of the least square error. The distance of the wound edge from the fixed edge of the 
cell layer was assumed to be very large compared to the gap size and cell diameter. In our 
optimization code, we observed that the results are insensitive to this value (data not shown).  
The following values were obtained for the motion of the lower edge: 
κ  = 5.92 µm2/hr, φ  = 0.86  
We repeated the data fitting for the upper layer where we averaged the position of cells 
U1-U5 located in the interior of the layer and the position of cells U6-U10 located near the edge. 
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We obtain the following values: 
κ  = 3.87 µm2/hr, φ  = 1.04 
The averages over both layers are κ  = 4.9 µm2/hr and φ  = 0.9.  As shown in Figure 2-5, 
the velocity of the cells at the edge is gradually decreasing while the velocity of cells in the 
interior of the layer is initially zero and then slowly increasing. 
 
 
 
 
 
 
 
 
                           
 
 
Figure 2-5: Dependence of traveled distance on time. Average distance traveled by cells in the direction perpendicular to 
the wound edge is shown as hollow diamonds (U1-U5 or L1-L5) and triangles (U6-U10 or L6-L10).  Computed 
predictions are shown as solid (edge), dashed and dash-dotted curves. 
A B
2.7 DEPENDENCE OF MIGRATION ON INTEGRIN CONCENTRATION 
The adhesion of cells to the substrate and the force exerted by lamellipodia are 
modulated by adhesion receptors, such as integrins, that connect the cell to the extracellular 
matrix. Integrin concentration and integrin-ligand affinity have been found to affect the speed of 
migrating cells (10). 
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 The present model allows us to investigate the effect of integrins on migration speed by 
examining the dependence of the constants b, k, and F on integrin concentration I.  At the present 
time this dependence is not known, however, the following assumptions appear reasonable: (i) 
the adhesion constant b should be proportional to I, (ii) the lamellipod force F should be 
proportional to I , and (iii) the stretching modulus k of the layer should be independent of I.  
The difference in scaling between b and F stems from the fact that adhesion is generated on the 
entire cell-matrix contact surface, while the force of the lamellipod is only exerted at the cell 
edge. Since our one-dimensional model represents a two-dimensional layer of cells, b is 
proportional to the area of contact between the cell and the substrate while F is proportional to 
length of the cell edge. Remarkably, under these simple assumptions the graph of migration 
Figure 2-6: Dependence of edge migration velocity on integrin concentration for three different time 
instants: t = 2h (circles), t = 4h (crosses), t = 6h (triangles).  Here . , and 16.1=φ90.4=κ, 0=ρ
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velocity versus integrin concentration in Figure 6 shows the characteristic bell-shaped curve with 
low velocity corresponding to low or high integrin concentration and maximum velocity 
corresponding to intermediate integrin concentration (10,11).  This observation is not meant to 
replace the detailed and quantitatively accurate model of the dependence of cell speed on 
adhesion (20), but rather to give some insight into the possible causes of observed velocity 
variability, such as may occur during inflammatory states. 
 
2.8 DISCUSSION 
The model developed in this paper accounts for the three effects influencing cell 
migration, i.e., the driving force of lamellipodia, the motion impeding adhesion between cells 
and the substrate, and the elasticity of the cell layer. In the case of constant proliferation, the 
model predicts increasing velocity of the wound edge. In the case of negligible proliferation the 
model predicts that the velocity of cells at the edge is initially greater and decreases with time, as 
is seen experimentally (26). This prediction differs dramatically from predictions of models 
based on reaction-diffusion equations in which the motion of the edge has constant or gradually 
increasing velocity. The velocity of cells in the interior of the layer is initially zero and then 
slowly increases, again in accord with observations.  In contrast, none of the existing reaction-
diffusion models makes predictions about the migration speed of cells in the interior of the layer. 
One important consequence of the model is that in the absence of proliferation the 
maximum distance traveled by any edge is finite. It follows that if the gap of the wound is 
sufficiently large, the remaining enterocyte layer may not be able to close the wound.  This 
 20 
phenomenon was observed experimentally in studies of enterocytes cultured on glass coverslips 
(see Figure 2-7) and is not easily explained by a model based on reaction-diffusion equations. 
 
 
 
 
 
At its present form the model yields ratios of the quantities of interest (κ  characterizes 
the ratio of the stretching modulus k of the layer to the adhesion coefficient b, and φ  is the ratio 
of the force F exerted by lamellipodia to the stretching modulus k) and hence the model enables 
us to make relative comparisons between these effects.  In order to obtain true magnitudes of F, b, 
or k, one would need to perform an independent measurement of at least one of the three 
quantities.  Prass et al. (27) have measured the cell stall force for keratinocytes using atomic 
force microscopy catilever and obtained a value ~40nN. If enterocytes migrating on glass 
coverslips exert similar force, then the corresponding value of the cell-layer stretching modulus k  
would be ~44 nN and adhesion/friction constant b would be ~0.11  hr·nN/µm2.  
Two different fits were performed in order to determine the coefficients κ and φ , one 
for the lower and one for the upper edge of the wound, yielding two different sets of parameters. 
Figure 2-7: Enterocyte migration is incomplete under conditions of excessive wound formation. IEC-6 cells were 
plated on glass coverslips, scraped to induce a wound, then allowed to undergo wound closure over the ensuing 
24h. The position of the wound edge at the beginning of the experiment (panel A) and 24 hours later (panel B) is 
indicated by the dotted line.  In B the dark cells in the wound have undergone apoptosis. 
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There are several possibilities as to likely sources of this difference.  One possibility is that the 
cover slip was locally inhomogeneous in adhesion properties, which would have affected both κ  
and φ  constants. Other sources of discrepancy could be local inhomogeneities in initial cell 
density or cell maturity.  
The model described herein is sufficiently general in that it allows for more general 
growth rate laws to be incorporated.  One extension would be to implement spatially variable 
growth rate )(sρ .  There are indications that the proliferation is increased in the area near the 
edge shortly after creation of the wound.  Another possibility is to make growth rate dependent 
on the stretch in the layer - stretched layer may be more likely to reproduce than compressed, 
crowded one. 
In summary, we have developed a simple model that accurately describes the migration 
of the enterocyte cell layer (both at the edge and in the interior) in terms of three characteristics: 
the adhesion of cells to substrate, the elasticity of the layer, and the force exerted by lamellipodia.  
Fitting of the model to measured data enables one to determine the magnitude of each of these 
characteristics as a function of the treatment conditions (such as the concentration of LPS). 
It is important to point out that while the current model is clearly applicable to the 
situation of scrape wounding of enterocyte monolayers on glass coverslips in vitro, it also 
provides for useful – albeit partial - information regarding the applicability to in vivo wound 
healing. For instance, although wound healing in vitro occurs in three dimensions and may be 
influenced by the presence of inflammatory cells that could serve to modify the rate and extent of 
healing that occurs, the researchers in Dr. David Hackam’s lab in University of Pittsburgh have 
recently demonstrated that the fundamental forces that drive wound healing within the intestine 
in vivo bear striking similarity to the in vitro situation described in the present study. The 
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similarities between in vitro migration of enterocytes and in vivo healing as occurs in NEC 
include a dependence on intact gap junction mediated cell-cell contacts for migration to occur 
(28), the inhibition of migration by inflammatory cytokines (e.g. IFN-γ) (28) and nitric oxide 
(29), and marked inhibition by pro-inflammatory macrophages that may be present within the 
sub-epithelial lamina propria (Anand et al, unpublished observations). Moreover, although 
proliferation of enterocytes must occur in order to replace cells that are lost due to damage, the 
role of enterocyte proliferation in the modulation of mucosal healing is significantly more 
important during chronic inflammatory states as opposed to the acute inhibition of healing as 
occurs during exposure to LPS (C. Leaphart et al, unpublished observations). Taken in aggregate, 
we submit that the current model provides important insights into enterocyte migration in vitro 
with useful correlates for the in vivo situation, both under basal conditions and during conditions 
of intestinal inflammation such as NEC. 
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3.0    TWO-DIMENSIONAL ELASTIC CONTINUUM MODEL OF ENTROCYTE 
LAYER MIGRATION 
In this chapter, I present a two dimensional model based on the laws of continuum mechanics 
for the enterocyte layer migration.  
3.1 INTRODUCTION 
In the previous chapter, we developed a simple but accurate model that describes the 
migration of the enterocyte cell layer. A natural extension of it is to have a similar model but in 
higher dimension and incorporates the same effects (i) mobility promoting force due to 
lamellipod formation, (ii) mobility impeding adhesion to the cell matrix and (iii) elasticity of the 
cell layer.  For the wound healing models, there exists a class of hyperbolic equation models 
which arise from mass conservation laws of densities of cells (36). This type of model is often 
used in the application of tumor growth modeling because the surface of the tumor is a free 
boundary and one seeks to determine both the tumor’s region and the solutions of the differential 
equations within the tumor (37). Similarly, to model closure of wound by enterocytes migration, 
we consider the boundary of the wound be a moving boundary as well. Based on the laws of the 
continuum mechanics, we derived a two-dimensional model that incorporates the same effects as 
our 1d model. To numerically solve the resulting problem, we developed a computational 
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method based on the classical finite element method for parabolic equation. Although our 
method is limited for certain computational domain, it successfully produces the desired 
qualitative results.    
3.2 MATHEMATICAL FORMULATION 
We consider the enterocyte layer as a two-dimensional continuum. By the laws in 
continuum mechanics we have: 
3.2.1  Conservation of Mass: 
)),(()(),( tg
t
t xAvx =⋅∇+∂
∂ ρρ                                    (3.1) 
where ρ  is the density of the cell, v represents the velocity at position x. The source term g is 
assumed to be zero because of absence of the proliferation, 
3.2.2 Balance of Linear Momentum: 
                                                                                                                                    (3.2)  Tfv =+ vv ⋅∇+∇⋅∂
∂ ρρρ )(
t
 
The above equation is also called Cauchy's differential equation. In our model, the body force 
f(x,t)  is the result of  the total friction on a material element exerted by the substrate and that is 
proportional to area:  
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                                                         ρ
vf b−=                                                        (3.3)                                        
3.2.3      Constitutive Equation  
IT p−=                                                           (3.4)   
where T is the stress tensor. The pressure p can be both positive (when cells are compressed) or 
negative (when they are stretched). 
            For the dependence of pressure on cell density, we have the following different choices:                            
1) The linearized form of Hooke’s law . It is appropriate for small changes 
in the density. The drawback of it is that the resultant stress remains finite if the material is 
compressed to infinitesimal volume.                                                                                                                         
)1( 1−−= −ρκp
2) The assumption from Ideal gas law .  It works for large density of the cell 
layer but is not good for small density. If the material stretches to infinite volume, the tension 
within the cells should go to infinite and it is clear that this assumption does not have this feature.                       
)1( −= ρκp
3) The following relation )ln(ρκ=p  is good for both large and small density. It yields 
infinite magnitude of the resultant stress for both infinitesimal and infinite volume.  
Moreover, as we shall see below, this choice leads to the standard moving boundary problem for 
heat equation, the Stephan problem. 
After we plug it into Eq 3.4 and it becomes: 
IT )ln(ρκ−=                                                    (3.5) 
Then we combine Eq. 3.2, Eq. 3.3 and Eq. 3.4 together, we get: 
))ln(()( ρκρρρρ ∇−−=∇⋅+∂
∂ vvvv b
t
                          (3.6) 
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After neglecting the material time derivative of the velocity, i.e., letting 0)( =∇⋅+∂
∂ vvv ρρ
t
, Eq. 
3.6 becomes: 
                                                         ))ln(( ρκ−∇=vb                                                   (3.7) 
Because the source term g in Eq. 3.1 is zero, Eq. 3.1 becomes.  
)(),( vx ρρ ⋅−∇=∂
∂
t
t
                                                (3.8)                                     
Thus we obtain Eq 3.7 and Eq. 3.8 that are analogous to Darcy’s law in the theory of flow 
through porous media. 
Let bk /κ=  and plugging Eq. 3.7 into Eq. 3.8, we get our two-dimensional elastic continuum 
model: 
                                                   )(
),( ρρ ∇⋅∇=∂
∂ k
t
tx
                                                   (3.9) 
To reduce it to our one-dimensional model, we have 1)( −∂
∂=
s
xρ  and 
t
xv ∂
∂= . After putting them 
into Eq. 3.7, we have 
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that is same as the Eq.2.11. 
3.2.4 Moving boundary initial value problem for heat equation 
                                                         ρρ ∇⋅∇=∂
∂ k
t
                                                    (3.10)           
To be general, we assume the initial density of tissue equals one on the initial domain. 
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Initial Condition:                  1)0,( =xρ                    on                                  0Ω
On the exterior boundary  (see Figure 3-1), we assume the domain is fixed and there 
is no in-flux for the cell. We note that this is agreed with the experiment setting. On the interior 
moving boundary , we assume the lamellipodia exerts a constant force –F (the negative sign 
means the force is outward and the cells are stretched). By Eq. 3.4 and our choice of dependence 
of pressure
t
2Ω∂
t
1Ω∂
)ln(ρκ=p , we get the boundary condition κ  on  . To reduce the number of 
parameters, we assume b=1, thus
ρ /Fe= t1Ω∂
κ=k . 
Boundary Condition:           0=⋅∇ nρ                     on                           t2Ω∂
kFe /=ρ                   on                         t1Ω∂
On the moving boundary , by Eq. 3.7, we have t1Ω∂
 )()1())ln(( /
1
ρκρρκρκ ∇−∇=∇−∇=−∇=
−
Ω∂
kFeb
t
v                     (3.11)  
We then derive the following equation. 
Thus, the motion of the boundary obeys the following condition.  
Stephan Condition:            nn ⋅∇=⋅ − ρkFkev /                  on                        t1Ω∂
 The vector n is the unit outward normal to .  t1Ω∂
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 Figure 3-1: Computational domain of moving boundary initial value problem Eq. 3.10 
3.3 NUMERICAL METHOD 
      Not like the classical heat equation, which is solved in the fixed domain, the boundary of our 
problem Eq. 3.10 is nonstationary. To determine the computational domain every time step, we 
can use its velocity from previous time step and solve the equation on its latest domain.  Based 
on this idea, we develop a modified Finite Element Method to solve this problem. 
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3.3.1 Finite Element Method (FEM) for parabolic equation on fixed domain 
3.3.1.1  Introduction 
The finite element method originated from solving for problems in the civil engineering and 
aeronautical engineering (39). Although there are many different types of FEM existing now, the 
essential characteristic of it is the mesh discretization of a continuous domain into a set of 
discrete sub-domains. Let us consider the standard parabolic equation that arises from our 
moving boundary problem Eq. 3.10: 
                                               ρρ ∇⋅∇=∂
∂ k
t
                        in  Ω                         
Initial Condition               1)0,( =xρ  
Boundary Condition:       0=⋅∇ nρ                               on    2Ω∂                    (3.12) 
                                                                        on   kFe /=ρ 1Ω∂        
where Ω  is a fixed convex domain in 2R  with smooth boundary 21 Ω∂∪Ω∂=Ω∂  . The vector n 
is the unit outward normal to .  Ω∂
3.3.1.2  Semidiscrete Galerkin approximation 
Definition: Hilbert Spaces   )(ΩmH
             First we introduce the vector space of square integrable functions on ,                     Ω
                                             }][{)(
2/1
2
02
∞<=≡Ω ∫Ω dxuuuL  
                                       }0),()({)( 22 mLuDLuH
m ≤≤Ω∈Ω∈≡Ω αα  
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 The initial-boundary value problem Eq. 3.12 can be replaced by the following equivalent 
Galerkin problem. Find a function ),( txρ , continuously differentiable with respect to t, such that 
S∈ρ and for all , we have 0Sv∈
                                                                             (3.13) 0vv =∇⋅∇+ ∫∫ ΩΩ xx dkdt ρρ
Where S is the set of functions: 
S= {v for each and ; and  on } and ={ )(),(,0 1 Ω∈⋅≤< HtvTt )(),( 2 Ω∈⋅ Ltvt kFetv /),( =x 1Ω∂ 0S
0)()(1 =Ω∈ xvHv  on }. 1Ω∂
          The solution to the Galerkin problem is also a solution of the initial-boundary value 
problem Eq 3.12. The converse requires a solution to the Galerkin problem to have additional 
smoothness.  
          We choose a finite-dimensional subspace  spanned by0SS
h ⊂ }1:{ Nii ≤≤φ . Here h is a 
mesh gauge that approaches 0 as ∞→N  and in our computation, we choose the triangular mesh 
and the basis function { iφ } be the piecewise linear functions i.e. 1=iφ at node  and zero 
elsewhere. Since we have Dirichlet boundary condition on
ix
1Ω∂ , we have the following 
semidiscrete Galerkin approximation to),t(u x ),( txρ . 
 
                                                                                                                                        (3.14) 
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         Where { iφ } with  is the basis function for node  on . The coefficients 
 are continuously differentiable functions of t on [0, T] and can be determined by the 
system of equations: 
pNiN +≤≤+1 ix 1Ω∂
)(tci
                                      ,              0=∇⋅∇+ ∫∫ ΩΩ xx dukdu iit φφ Ni ≤≤1                       (3.15)  
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 Substituting Eq. 3.14 into Eq. 3.15 gives a system of ordinary differential equations: 
                                                 FKCCM =+
dt
d                                                           (3.16) 
where the N x N mass matrix is: 
                                                                                                        (3.17) ∫Ω≡ xxxM djiji )()(, φφ
the N x N stiffness matrix is: 
                                                                                               (3.18) ∫Ω ∇⋅∇≡ xxxK dk jiji )()(, φφ
the N x 1 source vector is: 
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1
φφ                                         (3.19) 
and the N x 1 vector of unknows:                                                
                                                                                                             (3.20) Ti tct )]([)( =C
       
3.3.1.3  Complete discretization 
    Let 0>=Δ
N
Tt  be the time step and solution C(t) at tmtm Δ=  (m=1,2,..N) be .  The   
backward difference approximation of 
mC
dt
dC
 at  is defined as: mt
                                                              
t
mm
Δ
− −1CC
                                                        (3.21) 
Plugging Eq. 3.21 into Eq. 3.16 and evaluating C(t) at , we get the following Backward Euler 
approximation of Eq. 3.16:                
mt
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Rearranging the items of Eq. 3.22, we have: 
                                                                         (3.23)  )/()/( 11 −− Δ+Δ+= mm tt CMFMKC
3.3.1.4 Convergence of the semidiscrete solution 
In this section, we establish convergence of the semidiscrete Galerkin approximation 
to the true solution),( tu x ),( txρ .  Since we let  be a space of continuous, piecewise linear 
functions, we can choose the piecewise linear interpolant 
0SS
h ⊂
),(~ tu x be an approximation to ),( txρ  
(40). Further assume the initial condition that )00,(x ,() x)0,(~ x ρ== uu . 
Assume that      ∑ ∑
=
+
+=
+=
N
i
i
pN
Ni
k
F
ii etctu
1 1
)()()(~),(~ xxx φφ                                                    (3.24)     
Define for    , Ni ≤≤1
                              xx dukdutk iiti φφ ∇⋅∇+≡ ∫∫ ΩΩ ~~)(                                    (3.25) 
Let iv φ=  in Eq. 3.13. Subtracting Eq. 3.13 from Eq. 3.25, we have 
                   xx dukdutk iiti φρφρ ∇⋅−∇+−≡ ∫∫ ΩΩ )~()~()(                                    (3.26) 
and subtracting Eq. 3.14 from Eq. 3.25, we obtain: 
                xx duukduutk iiti φφ ∇⋅−∇+−≡ ∫∫ ΩΩ )~()~()(                              (3.27) 
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Let Eq. 3.28 equals to Eq. 3.29, we have: 
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We use the inequality 22
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1 baab +≤   to obtain the inequality in Eq. 3.30. Furthermore, using the 
equalities: 
                                       2
02
2
222 2
1
2
1 V
dt
ddV
dt
ddVV t == ∫∫ ΩΩ xx  
We can rewrite Eq. 3.30 as: 
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Integrating over t and by Gronwall’s lemma, we have  
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Theorem.   Let ),( txρ  be the solution to the parabolic initial-boundary value problem Eq.3.12 
and for each t le )t  be its semidiscrete Galerkin approximation. Assume that for each t, t ,(u ⋅
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 and ),( tt xρ  belo )(2 Ωn (n=2 for our two-dimensional case). The interp  ,(),( txρ ng on olantH )~ tu ⋅ of  
ρ  is in the form Eq. 3.24, such that 
                                                    )(~ 2 mn
m
hOu −≡−ρ ,                        m=0,1                   (3.33) 
as , then for , 0→h Tt ≤≤0
                                                      12
0
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where K depends on T and ρ . 
               Proof:   By the triangle inequality, 
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By Eq. 3.33, the first term on the right is . For the second term, it is bounded by the square 
root of the right side of Eq. 3.32.                                                             
)( 12 −nhO
Furthermore, since tu~  is the interpolant of tρ  and Eq. 3.33 holds also for mtt u~−ρ , we have  
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 Thus substituting it into Eq. 3.32, we have that for fixed t, 
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3.3.2 Algorithm   
3.3.2.1  Main   procedure             
Because our problem has the time-dependent boundary, we can not apply the standard 
finite element method for the parabolic equation directly. In order to solve this moving boundary 
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problem, we design the following computation method: (See Figure 3-2 for general procedure 
and Table 3-1 for details). 
 
Figure 3-2: The general computation procedure for solving the moving boundary initial value problem  Eq. 3.10 
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Table 3-1: The details of the algorithm for computing moving boundary initial problem Eq. 3.10 
1. Get the initial mesh M(0) on the initial domain 0Ω by using MATLAB mesh 
generator DistMesh (41). 
2. Get new mesh M(i) at time step i,  1≥i
2.1 Calculate ρ∇ iiΩ∂on the triangles along the moving boundary  
2.2 Calculate the velocity on these triangles by using Stephan 
condition: v  nn ⋅∇=⋅ − ρkF/ke
2.3  Get new mesh points and generate new mesh M(i), i  (See 
next section for details )   
1≥
  
3. Solve solution on the new mesh M(i) 
3.1   Set solution C(i) equal e on  the new moving boundary. kF/−
3.2  Get the Mass Matrix M, Stiff Matrix K and source vector F by 
using MATLAB routine “assema.m” 
3.2   Solve solution C(i+1)  by  Backward Euler Method: 
))(/()/()1( 1 itti CMFMKC Δ+Δ+=+ −  
3.3   Goto 2 
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3.3.2.2  How to get new mesh M(i) 
 
 
 
 
  This figure above shows how we get the new mesh M(i) at time step i.  For instance, we 
consider the mesh points A, B and C on the moving boundary of M(i-1). By moving AB and BC 
parallel in the normal direction of their velocities and by tvΔ  units, we can solve their 
intersection point E which is also the new mesh point. Similarly we can get the new mesh point F. 
But for a special case (See Figure 3-4), if AB and CD intersect before they intersect with BC, we 
have to merge the mesh points E and F. By connecting the new mesh points E and F (Figure 3-3) 
or E (Figure 3-4) to their corresponding old mesh points A,B,C and D and repeating the same 
procedure for all the mesh points on the moving boundary of M(i-1), finally we obtain the new 
mesh M(i).  
Figure 3-3: The diagram that shows how to obtain the new mesh M(i) at time step i. A,B,C and D are the mesh 
points on the moving boundary of  mesh M(i-1). E and F are the new mesh points.  
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Figure 3-4: The diagram that shows a special case of how to obtain the new mesh M(i) at time step i. A,B,C and 
D are the mesh points on the moving boundary of  mesh M(i-1). E is the new mesh points.  
3.4 NUMERICAL RESULTS: 
The following are the computation results: 
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A 
Figure 3-5: (A) The initial finite element triangular mesh M(0) of Eq. 3.10 
in ellipse domain. (B) The initial solution of Eq. 3.10 with F=1 and k=1. 
B 
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A 
B 
Figure 3-6: (A) The finite element mesh M(i) at time step i, where i=100, 
T=2 and  
100
Tt =Δ .  (B) The initial solution of Eq. 3.10 with F=1 and k=1. 
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Figure 3-7:  The plot of solution of Eq. 3.10 at t=2 with 50
1=Δt , F=1 and 
k=1. 
 
 
 
3.5 DISCUSSION 
         In this chapter, we developed a two-dimensional partial differential model based on the 
laws of continuum mechanics.  Like our 1d model in the previous chapter, it also accounts for 
the three effects that influencing the cell migration, i.e., the driving force of lamellipodia, the 
motion impeding adhesion between cells and the substrate and the elasticity of the cell layer. To 
numerically solve the resulting moving-boundary problem, we developed a computation method 
based the classical finite element method. We should note that the method we choose here works 
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only for certain geometry (round, ellipse) domain and also we have not calibrated our parameters 
in the model because of absence of the experimental data.          
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4.0  AGENT-BASED MODEL OF INFLAMMATION AND WOUND HEALING IN 
DIABETIC FOOT ULCER 
In this chapter, I present a computational model for simulating the behavior of complex 
system in the wound healing process of Diabetic Foot Ulcer.  
4.1 INTRODUCTION 
Diabetic foot ulcers (DFU) are caused by both vascular and neurologic complications of 
diabetes, in combination with persistent opportunistic infections (56,57) and deficient wound 
healing (58). Over 10 million Americans carry a diagnosis of diabetes, and an estimated 5 
million more are undiagnosed diabetics (59). The incidence of foot ulcer in this population 
approaches 2% per year (60).  With reported average treatment costs ranging from $2,500 to 
almost $14,000 per year, diabetic foot ulcers (DFU) represent a significant financial burden on 
society (58,60).  Additionally, DFU are responsible for more than 50,000 major lower extremity 
amputations in the United States every year (61). Notably, diabetics with foot ulcers have more 
than twice the mortality of diabetics with healthy feet (62). Diabetics are known to have elevated 
levels of TNF (63), and studies have suggested a relatively reduced expression of active TGF-β1 
in DFU (64). Both inflammation and wound healing are deranged in chronic, non-healing foot 
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ulcers, constituting a major complication of diabetes.  
Wound healing is a process that involves both inflammation and the resolution of the 
inflammatory response, which culminates in remodeling (42,43). The first phase of the wound 
healing response involves the degranulation of platelets and infiltration of inflammatory cells, 
followed by proliferation of fibroblasts and epithelial cells that deposit collagen and cause 
contraction of wounds. Rodent models of diabetes display impaired wound repair, with 
decreased wound tensile strength and collagen deposition in implanted sponges (44).  Collagen 
organization in healing wounds is also poor (44). Furthermore, diabetic wounds have deficits in 
neovascularization (4) and decreased levels of DNA and protein (44).  Pro-inflammatory 
cytokines such as tumor necrosis factor-α (TNF)(5) and interferon-γ (IFN-γ)(47) inhibit wound 
healing both in vitro and in vivo. Interleukin-6 (IL-6), a cytokine central to inflammation (48), is 
also necessary for proper healing (49). Interleukin-10 (IL-10), a potent anti-inflammatory 
cytokine, appears to suppress inflammation and induce the remodeling necessary for proper 
wound healing (50). One cytokine that is central to the wound healing cascade is transforming 
growth factor-β1 (TGF-β1) (51). TGF-β1, like all isoforms of TGF-β, is produced in a latent 
form, which must be activated in order to exert its biological effects.  The TGF-β1 precursor 
homodimerizes intracellularly, and is then cleaved extracellularly to yield the active TGF-β1 
dimer as well as the remaining portion of its dimerized precursor, the latency-associated peptide 
(LAP).  Under physiological conditions, TGF-β1 is expressed almost completely in its latent 
form, which consists of the active TGF-β1 dimer bound non-covalently to LAP.  Additional 
proteins such as α2-macroglobulin, latent TGF-β binding proteins, or proteoglycans (e.g. 
decorin) are bound to latent TGF-β1 in what is known as the large latent complex.  Latency-
associated peptide and other proteins must be dissociated from latent TGF-β1, in a process 
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known as activation, before TGF-β1 gains biological activity (52).  Of note, there are multiple 
regulatory intersections among TNF, IL-6, IL-10, IFN-γ, and TGF-β1 (53), and much of this 
complexity has been captured in our equation-based models of inflammation (54,55).  
A standard treatment for DFU is wound debridement, which is effective in 
approximately 25% of patients (65). In an attempt to improve healing further, numerous studies 
in animal models of diabetic wound healing have demonstrated efficacy of single growth factors 
such as platelet-derived growth factor (PDGF) (66), fibroblast growth factor (FGF, acidic or 
basic) (65), or TGF-β1 (65), these results have often not borne fruit when carried to clinical trials 
of DFU (67).  Though these therapeutic failures suggest that studies should be carried out on 
DFU patients and tissue/cells derived from these ulcers, we believe that such studies alone are 
likely insufficient due to the complexity of the wound healing process (68), the complexity of 
inflammation from which this process stems (53), the co-morbidities (56) and genetic variability 
in genes such as TGF-β1 (69) in the inflammation/wound healing responses of individual 
patients.  
 
4.2 MATERIALS AND METHODS 
4.2.1 Agent-based Model of Inflammation and Wound Healing 
 The popularity of ABM lies in the fact that this type of model can simulate the behavior 
of complex systems in which agents interact with each other and with their environment 
following local rules based on known physiology. Moreover, the ABM framework accounts for 
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Figure 4-1:  The simulation region of Agent 
Based Model. Red: blood , Blue: tissue. 
the stochastic nature of biological processes, in that each rule is a probability of a given event 
happening; thus, each simulation leads to a unique outcome and can be considered as a separate 
experiment (or “virtual patient”) (79,75). A typical ABM includes three types of elements: 
region, patch and agent. The region consists of small patches that are uniquely characterized by 
spatial position, and contain local information. Agents are the objects that can move in the region.  
The motion of all agents is due to both chemoattraction and stochastic walk, as described in 
greater detail in the Appendix B.  We designed an 
ABM to simulate inflammation and wound healing 
in a physical domain including skin and underlying 
soft tissue (the tissue), using Netlogo software 
(Center for Connected Learning and Computer-
Based Modeling, Northwestern University, 
Evanston, IL). First, we created two regions to 
simulate blood (the source of some of the 
inflammatory cells that infiltrate injured tissue) and the 
tissue itself (which contains some inflammatory cells as 
well as the fibroblasts that will eventually act to heal the injured tissue) (Fig. 4-1). The two 
regions (blood and tissue) do not intersect: the tissue region is circular and surrounded by the 
blood region. We used agents to represent the damage (induced by the initial injury as well as by 
subsequent inflammation, and also a stimulus for further inflammation), as well as resting and 
activated inflammatory cells (neutrophils, macrophages and fibroblasts). We also used patch 
variables to represent latent TGF-β1 and the mediators produced by these cells during the 
inflammation and wound healing stages. The mediators include the pro-inflammatory cytokines 
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IL-1β and TNF (both produced by neutrophils and macrophages); the anti-inflammatory 
cytokines TGF-β1 and IL-10 (both produced by macrophages); and collagen (produced by 
fibroblasts)(76). Initially, some resting macrophages, neutrophils, fibroblasts and latent TGF-β1 
are present with a random distribution both in tissue and blood.  By stimulating the tissue with 
damage in the middle of region, the model creates a chemoattractant gradient (induced by 
platelet degranulation) (77), which acts to induce the infiltration and activation of both 
neutrophils and macrophages. Fibroblasts are activated at a later stage both by damage and TGF-
β1, to produce collagen that acts to repair both the initial and inflammation-induced damage (77).  
For a detailed description of rules, please see Appendix B. 
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4.3 RESULTS 
4.3.1 Simulating normal tissue healing 
 
 
 
 
Our ABM was capable of reproducing the qualitative features and general time course 
of skin wound healing, with regards to the dynamics of neutrophils, macrophages, and fibroblasts 
(Fig. 4-2A); and the inflammatory cytokines IL-1, IL-10, and TNF (Fig. 4-2B). The values in the 
figures are averaged over the entire space (also in all subsequent figures). Collagen deposition 
and tissue damage variables served as surrogates for wound healing, and these, too, exhibited the 
expected qualitative behavior with wound resolution occurring in approximately 1 month (Fig. 4-
2C). The simulation presented is one run, representative of the behavior of the ABM under these 
baseline conditions. In later simulations (see below), we show the variability across simulations 
at defined time points in the inflammation/healing process. Notably, this simulation did not 
Figure 4-2:   Simulations of baseline wound healing. Simulations using the ABM were carried out to 
30 days, and show the dynamics of inflammatory cells (Panel A), cytokines (Panel B), collagen (Panel 
C, left y-axis), and tissue damage (Panel C, right y-axis) 
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address aspects of longer-term collagen remodeling since this aspect of healing was not 
incorporated in the ABM.  
 
4.3.2 Comparison of normal vs. DFU healing  
 
 
 
 
 
Figure 4-3:   Simulations of healing trajectories in Normal, TNF-high, and TGF-β1-low cases. The 
simulated recovery of normal skin tissue damage (i.e., wound healing; solid line) is compared to one of 
two hypothetical derangements underlying DFU: elevated TNF production (dotted line) or reduced 
capacity to produce TGF-β1 (dashed line). 
We hypothesized that, since inflammation is the initial driver of wound healing, that 
inflammatory derangements seen in DFU might underlie the delayed healing characteristic of 
these lesions. Previous studies have suggested that macrophages from diabetics exhibit elevated 
TNF production (63), and other studies have demonstrated reduced expression of active TGF-β1 
(64). TNF and TGF-β1 cross-regulate their own expression and activity in diverse and complex 
ways, with TNF generally inducing the expression of TGF-β1 and TGF-β1 suppressing the 
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expression of TNF (78). Accordingly, we hypothesized that either derangement alone might be 
sufficient to result in altered healing. To test this hypothesis, we simulated the effects of elevated 
TNF or reduced TGF-β1. In Fig. 4-3, we show the healing trajectories (shown as dynamics of 
tissue damage) of normal (solid line, reprised from Fig. 4-2C), TNF-high DFU (dotted line), and 
TGF-β1-low DFU (dashed line). As can be seen, simulated damage in the DFU settings remains 
elevated as compared to normal wound healing, which we interpret as delayed healing. Thus, as 
suggested previously (70), the healing trajectories of DFU in these simulations are clearly 
delayed as compared to normal skin healing.  Importantly, this is an emergent property of the 
system, since the various observations indicative of DFU-like healing have not been 
programmed into the simulation but rather emerge as a result of changing a single variable 
(either TNF or TGF-β1). 
4.3.3 Simulating clinical variability and known therapies for DFU   
We wished to determine if our ABM would result in the sort of patient-to-patient 
variability that is typically observed clinically with regards to DFU healing. Accordingly, we 
varied --- and examined our scenarios of normal (Fig. 4-4A), TNF-high (Fig. 4-4B), and TGF-
β1-low (Fig. 4-4C) wound healing. These figures show that TNF-high and TGF-β1-low 
conditions result in higher levels of tissue damage, though our ABM exhibits the type of inter-
individual variability previously shown in ABM of acute inflammation (75).  
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Debridement, or physical removal of dead or dying tissue, is part of the routine care for 
DFU, and has been reported to improve healing in ~25% of patients (65).  Accordingly, we 
simulated this procedure by making the assumption that approximately 75% of damaged tissue 
would be removed at either day 7 or 14 into the time course of healing. Simulated tissue damage 
was then assessed at day 30. These simulations were carried out in the presence of the inter-
individual variability depicted in Figs. 4A-C, in an attempt to determine if the type of variability 
observed in clinical trials would be seen. Fig. 4-5A demonstrates the elevated damage at 
simulated day 30 in both TNF-high and TGF-β1-low DFU as compared to normal healing. 
Interestingly, our simulation suggests that collagen content would be elevated relative to normal 
healing if DFU were caused by elevated TNF, but the predicted collagen content of DFU derived 
from low TGF-β1 is predicted to be no different from that of normal controls (Fig. 4-5B). 
Debridement at day 7 was predicted to result in statistically significant reductions in tissue 
damage in both TNF-high and TGF-β1-low DFU (Fig. 4-5A). Interestingly, this effect of 
simulated debridement did not reach statistical significant when simulated debridement was 
Figure 4-4:  Simulation of the variability in healing trajectories in Normal, TNF-high, and TGF-β1-
low cases. Ten simulations for each case of normal, TNF-high, and TGF-β1-low skin healing were 
carried out, and the time courses of predicted damage/dysfunction are shown 
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performed at day 14. In contrast, debridement was not predicted to result in decreased collagen at 
day 7 or 14, in either TNF-high or TGF-β1-low DFU. These results are in general agreement 
with clinical studies of debridement (65). We note that in subsequent simulations below, 
debridement was not simulated in order to be able to gain insight into the single manipulation 
being studied. 
 
 
 
 
 
 
 
We also simulated biological therapies for DFU. Although multiple randomized 
prospective clinical trials have been performed using growth factors in the treatment of DFU, 
only PDGF has been approved for use (79).  PDGF, which is released from platelet granules 
(80), has been found to increase healing in diabetic neuropathic foot ulcers and is marketed as 
REGRANEX™ (81). There is also limited evidence to suggest clinical benefit from a platelet 
releasate that contains many growth factors including PDGF (67,82-84). In order to further 
validate our ABM, in which platelets are one class of agent, we assessed predicted tissue damage 
Figure 4-5:  Simulation of debridement of DFU. Debridement (“Debr.”) was simulated as removal of 75% of 
damaged tissue at the indicated day (either 7 or 14 days post-wounding) in either of two hypothetical derangements 
underlying DFU: TNF-high or TGF-β1-low (see Supplementary Materials for details of normal, TNF-high, and 
TGF-β1-low simulations.. Simulated tissue damage (Panel A) or collagen content (Panel B) was assessed at day 30 
post-wounding. Asterisk: P < 0.05 vs. Normal; † = P < 0.05 vs. TNF-high. 
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in the setting of increased platelet-derived factors. We simulated this increase by increasing 
separately the chemoattractant effect of platelets on macrophages and neutrophils (both effects 
being parameters in our ABM; see Appendix B).  As seen in Fig. 4-6, increasing the 
chemoattractant effect of platelets on macrophages by 70% and the chemoattractant effect of 
platelets on neutrophils by 18% resulted in reduced damage under both the increased TNF 
(dotted line) and reduced TGF-β1 (solid line) cases (compare to the same simulations in Fig. 4- 
3). 
                       
                         Figure 4-6:  Simulation of PDGF / platelet release therapy for DFU. The simulation of Fig. 4-3 was 
repeated, this time in the presence of elevated effects of platelets (increasing the effect of platelets on 
macrophages by 70% and the effect of platelets on neutrophils by 18%) 
 
 
This finding arose from a systematic modulation of the relative chemoattracts effects of 
platelets on macrophages and neutrophils, in a further attempt to explore the potential for our 
ABM to reproduce inter-patient variability (Tables 4-1 and 4-2). Interestingly, different ratios of 
the effects of platelets on macrophages and neutrophils were predicted to be either efficacious or 
non-efficacious at reducing tissue damage in a non-intuitive manner. In the ABM, activated 
macrophages are assumed to produce TGF-β1, which promotes the healing of DFU and inhibits 
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TNF production by neutrophils (see the TGF-β1 rule in the Appendix B). In turn, activated 
neutrophils are assumed to produce TNF which not only causes damage but also inhibits TGF-β1 
(see the TNF and damage rules in the Appendix B). By changing the different potency of 
activation of macrophages and neutrophils by platelets, the ABM produces different amounts of 
activated macrophages and activated neutrophils. This change, in turn, leads to the different 
predicted profiles of TGF-β1, TNF, and damage. Because of these dynamics, either beneficial of 
detrimental effects of platelets on macrophages and neutrophils are predicted. In all cases, 
benefit was predicted if the effect of platelets on macrophages was greater than the effect of 
platelets on neutrophils, and this held true whether we assumed that the underlying cause of DFU 
was elevated TNF (Table 4-1) or reduced TGF-β1 (Table 4-2). Non-intuitively, if the parameter 
governing the chemoattractant effect of platelets on neutrophils grew above a certain threshold, 
the predicted damage was higher than without therapy. We interpret this outcome as signifying 
that tissue damage mediated by neutrophils exceeds the beneficial effects of the pro-healing 
elements derived from macrophages. These results may explain why some patients respond to 
PDGF or platelet releasate and some do not (82,83). 
Table 4-1. Simulation of DFU therapy-1. The predicted effect on tissue damage of 
increasing the chemoattraction of platelets on macrophages (P1) and neutrophils (P2) was 
simulated. Macrophages are activated by platelets if the number of platelets is greater than (100 
/(1+M*M))/(1+P1), and neutrophils are activated by platelets if the number of platelets is greater 
than (100/(1+M*1.7)*(M*1.7))/(1+P2). At baseline, P1 = P2 = 0. In this case, DFU were 
assumed to arise from elevations in TNF production. Healing (assessed at 4-6 days) was assumed 
to occur if the predicted damage was lower than that predicted for the untreated DFU (8000 
arbitrary units; see Fig. 2A, dotted line). 
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 P1 (% 
increase over P1 in 
the TNF-high 
simulation [Fig. 2a]) 
P2 (% 
increase over P2 in 
the TNF-high 
simulation [Fig. 2a]) 
Damage 
(Arbitrary Units) 
Healing 
(relative to no 
treatment) 
129 19 892 Yes 
129 39 5600 Yes 
129 ≥59 >8000 No 
95 19 2000 Yes 
95 39 2070 Yes 
95 ≥59 >8000 No 
69 19 2700 Yes 
69 ≥39 >8000 No 
44 19 3100 Yes 
44 ≥39 >8000 No 
34 19 4000 Yes 
34 ≥39 >8000 No 
22 ≥19 >8000 No 
 
Table 4-2. Simulation of DFU therapy-2. The predicted effect on tissue damage of 
increasing the chemoattraction of platelets on macrophages (P1) and neutrophils (P2) was 
simulated. Macrophages are activated by platelets if the number of platelets is greater than (100 
/(1+M*M))*(1+P1), and neutrophils are activated by platelets if the number of platelets is 
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(100/(1+M*1.7)*(M*1.7))/(1+P2). At baseline, P1 = P2 = 0. In this case, DFU were assumed to 
arise from reduced TGF-β1 production. Healing (assessed at 4-6) was assumed to occur if the 
predicted damage was lower than that predicted for the untreated DFU (3000 arbitrary units; see 
Fig. 2A, dashed line). 
P1 (% 
increase over P1 in 
TGF-β1-low 
simulation [Fig. 2a]) 
P2 (% 
increase over P2 in 
the TGF-β1-low 
simulation [Fig. 2a]) 
Damage 
(Arbitrary Units) 
Healing 
(relative to no 
treatment) 
170 19 1400 Yes 
150 19 1600 Yes 
129 19 2000 Yes 
129 >39 >3000 No 
95 ≥19 >3000 No 
69 19 2700 ~Equal 
69 ≥39 >3000 No 
44 19 2300 Yes 
44 ≥39 >3000 No 
34 19 3500 No 
34 ≥39 >3000 No 
22 ≥19 >3000 No 
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4.3.4 Inflammatory and Healing Characteristics of simulated DFU 
Having demonstrated that the overall qualitative simulations are valid, we next wished to 
examine the characteristics associated with healing in simulations of normal tissue and the two 
ways of simulating DFU (TNF-high and TGF-β1-low). These simulations were all examined at 
2.5 days in order to examine early drivers of the inflammatory and healing responses. In all 
cases, we carried out ten simulations of each condition, since the ABM platform is inherently 
stochastic (85). This approach allowed us to simulate several “patients” and also to carry out a 
statistical analysis (Kruskall-Wallis ANOVA on ranks followed by Tukey post-hoc test) to 
ascertain group differences (considered significant at P < 0.05). As seen in Fig. 4-7, the 
qualitative features of simulated wound healing either in the setting of elevated TNF production 
(gray bars) or reduced TGF-β1 production (hatched bars) as compared to normal healing (black 
bars) are largely similar: elevated neutrophil influx (Fig. 4-7A), elevated TNF expression (Fig. 4-
7B), elevated IL-10 (Fig. 4-7C), reduced collagen deposition (Fig. 4-7E), and increased tissue 
damage (Fig. 4-7F). In general, these are all hallmarks of DFU. Interestingly, decreased TGF-β1 
expression as compared to normal healing was observed in the simulations in which DFU were 
presumed to arise from reduced TGF-β1 (as expected, Fig. 4-7D, hatched bar), but this was not 
the case in simulations in which TNF was over-produced (Fig. 4-7D, gray bar). 
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Figure 4-7:  Simulations of inflammation and healing parameters in normal, TNF-high, and TGF-
β1-low cases. The simulated levels of neutrophils (Panel A), TNF (Panel B), IL-10 (Panel C), TGF-β1 
(Panel D), collagen (Panel E), and tissue damage (Panel F) are shown for normal skin healing (black 
bars) and two hypothetical derangements underlying DFU: elevated TNF production (gray bars) or 
reduced capacity to produce TGF-β1 (hatched bars). *: P< 0.05 vs. Normal; †: P< 0.05 vs. TGF-β1-low 
(all by Kruskall-Wallis ANOVA on ranks followed by Tukey post-hoc test). 
4.3.5 Simulating hypothetical therapies for DFU   
We next sought to simulate therapies for DFU. Numerous studies in animal models of 
diabetic wound healing have demonstrated the efficacy of topical administration of single growth 
factors such as PDGF (66), acidic or basic FGF (44), or TGF-β1 (44).  However, these results 
have not been confirmed in clinical trials of DFU (79). In an attempt to determine if in silico 
methodologies could suggest some insights into therapy design for DFU, we applied simulated 
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therapeutic strategies to our simulations of delayed healing depicted in Fig. 4-7. Since both 
elevated TNF and reduced TGF-β1 gave generally similar qualitative patterns of inflammatory 
and healing derangements, we tested the simulated therapies under settings of either elevated 
TNF (Fig. 4-8) or reduced TGF-β1 (Fig. 4-9). The therapies we chose to simulate are directly 
related to these derangements: neutralizing antibodies to TNF (anti-TNF), agents that increase 
the rate of TGF-β1 activation, and latent TGF-β1 itself. The rationale for these interventions was 
the following. In the case of anti-TNF, FDA-approved anti-TNF antibodies are available for the 
treatment of several inflammatory diseases, with further indications likely (86); additionally, we 
have carried out previous work on simulating mathematically the actions of anti-TNF in the 
setting of sepsis (87). TGF-β1 modulation (either provision of TGF-β1 or its inhibition) has been 
proposed as a possible therapy for various aspects of aberrant wound healing (88). TGF-β1, like 
all other isoforms of TGF-β, is synthesized in a biologically inactive (latent) state and must be 
activated through various mechanisms in order to bind to its cognate receptor complex and exert 
its diverse biological functions (52). Treatment with active TGF-β1 as well as TGF-β2  has been 
attempted in the setting of DFU, with initially promising results but ultimately lack of 
statistically significant efficacy (54,55). One reason for this lack of overall efficacy might be that 
active TGF-β1 has a shorter half-life than latent TGF-β1 (52). In the case of TGF-β1 activation, 
As seen in Figs. 4-8 and 4-9, we carried out ten simulations of each condition, and assessed 
statistical significance by Kruskall-Wallis ANOVA on ranks followed by Tukey post-hoc test.  
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Figure 4-8: Simulations of therapies in TNF-high DFU. The simulated levels of neutrophils (Panel A), 
TNF (Panel B), IL-10 (Panel C), TGF-β1 (Panel D), collagen (Panel E), and tissue damage (Panel F) are 
shown for skin healing in DFU assumed to arise due to elevated TNF production (black bars). Also 
simulated are three hypothetical therapies: anti-TNF neutralizing antibodies (hatched bars), an agent that 
activates endogenous latent TGF-β1 (gray bars), and treatment with latent TGF-β1 (open bars). *: P< 
0.05 vs. TNF-high baseline; †: P< 0.05 vs. TGF-β1 activator; #: P< 0.05 vs. anti-TNF (all by Kruskall-
Wallis ANOVA on ranks followed by Tukey post-hoc test) 
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Regardless of whether DFU healing was simulated as stemming from elevated TNF 
production (Fig. 4-8) or reduced TGF-β1 production (Fig. 4-9), all three therapies (anti-TNF 
[hatched bars], latent TGF-β1 [open bars], or TGF-β1 activation [gray bars]) were predicted to 
suppress neutrophil influx (Figs. 4-8A and 4-9A) and tissue damage (Figs. 4-8F and 4-9F) to the 
same, statistically significant degree as compared to the DFU baseline (black bars). Interestingly, 
Figure 4-9:  Simulations of therapies in TGF-β1-low DFU. The simulated levels of neutrophils (Panel 
A), TNF (Panel B), IL-10 (Panel C), TGF-β1 (Panel D), collagen (Panel E), and tissue damage (Panel F) 
are shown for skin healing in DFU assumed to arise due to reduced TGF-β1 production (black bars). 
Also simulated are three hypothetical therapies: anti-TNF neutralizing antibodies (hatched bars), an agent 
that activates endogenous latent TGF-β1 (gray bars), and treatment with latent TGF-β1 (open bars). *: P< 
0.05 vs. TGF-β1-low baseline; †: P< 0.05 vs. TGF-β1 activator; #: P< 0.05 vs. anti-TNF (all by Kruskall-
Wallis ANOVA on ranks followed by Tukey post-hoc test). 
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our simulations suggested that all three therapies would result in a reduction of TNF production 
in DFU tissue (Fig. 4-8B and 4-9B), though the effect of anti-TNF would not be statistically 
significant if the cause of DFU was elevated TNF production. Our simulation suggested that 
provision of latent TGF-β1 or activation of endogenous TGF-β1 would elevate overall TGF-β1 
expression regardless of the presumed cause (high TNF or low TGF-β1) of DFU pathology 
(Figs. 4-8D and 4-9D). Interestingly, only the TGF-β1 activator was predicted to increase 
collagen deposition in a statistically significant fashion, and only upon assumption of reduced 
baseline TGF-β1 as a cause of DFU. Another non-intuitive finding was the suggestion that anti-
TNF would decrease collagen levels above those of baseline DFU (Figs. 4-8E and 4-9E), while 
at the same time reducing overall tissue damage (Figs. 4-8F and 4-9F).  
 
4.4 DISCUSSION  
Chronic wounds are a serious health care problem, costing billions of dollars each year 
and carry unaccounted but considerable suffering and anguish.  DFU, in particular, are a major 
cause of amputation (58,60).  There has been great interest in treating DFU with growth factors 
in recent years.  One might suggest that use of growth factors to heal a DFU would result in 
improved healing and a lowered amputation rate (79).  Unfortunately, the number of amputations 
performed in the United States each year remains essentially unchanged (58,60).  
In order to attempt to break the logjam of compounds available for clinical trials in the 
setting of DFU, we created an ABM simulation of the inflammation/wound healing process. Our 
 63 
specific objectives were 1) to use this ABM to test hypotheses regarding the genesis of DFU and 
2) to test in silico possible therapies for DFU.  In the process of validating our ABM, we were 
able to simulate existing therapies for DFU (debridement and platelet releasate / PDGF). 
The literature regarding the inflammatory genesis of DFU is sparse. However, two 
possible mechanisms stand out: elevated TNF (63) and reduced TGF-β1 (64). Since both of these 
cytokines are highly interrelated in their biology, we incorporated several of these interactions in 
our model. Our simulations suggest that for many indices of inflammation and healing, the 
effects of elevated TNF and reduced TGF-β1 are very similar. Due to the interrelationships 
between TNF and TGF-β1, both elevated TNF and reduced TGF-β1 are predicted to be 
associated with increased inflammatory infiltrates, elevated TNF and IL-10, reduced collagen, 
and elevated tissue damage. However, only the simulation in which TGF-β1 is reduced, and not 
the case in which TNF is elevated, is predicted to be associated with the reported decreased 
expression of TGF-β1 in DFU (44). Thus, our simulations support the hypothesis that a central 
derangement in skin healing that leads to DFU is the reduced expression of TGF-β1. 
Nonetheless, it is possible or perhaps even likely that more than one cause of DFU exists. Given 
the overall qualitative similarity between the features of healing in the setting of reduced TGF-β1 
and elevated TNF, both mechanisms (and others as well) may be operant in DFU. Further 
clinical studies are needed in order to address this issue. In any case, these different assumptions 
can be used in the in silico design and testing of DFU therapeutics, since this variability could be 
used to create simulated clinical trials; we (44,87) and others (75) have demonstrated the utility 
of this approach in the setting of sepsis. 
Whether elevated TNF or reduced TGF-β1 underlies the pathology of DFU, our ABM is 
capable of reproducing the effect of known therapies for DFU. A major type of intervention is 
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debridement, in which necrotic and/or infected areas of a DFU are removed surgically. Studies 
have shown that debridement improves healing in ~25% of patients (65). When we simulated the 
removal of 75% of damaged tissue at either 7 or 14 d from the onset of a wound, our ABM 
suggested that this would result in a statistically significant reduction in tissue damage at 30 d 
without a change in collagen levels, interpreted by us to mean improved healing. It might be 
argued that our finding of reduced tissue damage upon simulated removal of damaged tissue 
would seem obvious, but the finding that collagen levels remain the same suggests that indeed 
our ABM is depicting healing.   
Although multiple randomized prospective clinical trials have been performed using 
growth factors in the treatment of DFU, only one growth factor, PDGF, has been approved for 
use (79).  PDGF has been found to increase healing in diabetic neuropathic foot ulcers and is 
marketed as REGRANEX™ (81). There is only limited evidence to suggest clinical benefit from 
other growth factors, including TGF-β1, FGF, IGF-1, GM-CSF, EGF, or a platelet releasate that 
contains many growth factors (79,82,83,94-101). In our simulation, we account for the effects of 
platelet releasate and PDGF through the inclusion of platelets which function to chemoattract 
macrophages and neutrophils (see Tables 4-1 and 4-2 as well as the Appendix B). Though we do 
not simulate PDGF explicitly, we demonstrate that modulating the actions platelets on 
macrophages and neutrophils can, under certain circumstances, result in reduced tissue damage 
as compared to that predicted to be found in untreated DFU. Moreover, our exploration of the 
relative effects of platelets on macrophages and neutrophils suggested that there would be great 
variability in the efficacy of platelet-related therapies (either PDGF or platelet releasate). Thus, 
these simulations may be of benefit when attempting to personalize this type of therapy to an 
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individual patient, if ex vivo studies could be carried out to assess the chemoattractant effect of 
the therapeutic agent on a patient-by-patient basis. 
This interaction between inflammation and wound healing in the setting of DFU therapy 
may also be seen in other ways. In the clinical trials of PDGF, the importance of debridement 
became apparent.  The first clinical trial to demonstrate benefit from PDGF found that extensive 
debridement, that is, wound excision down to normal tissue beyond the wound space, was 
associated with the highest healing rate (65). “Wound excision” was favored, as this procedure 
removed the tissue with the highest bacterial load and the highest concentration of proteases.  It 
may also be that the tissues removed were those trapped in the inflammatory phase of healing, 
with elevated TNF and reduced TGF-β1, a clinical observation that supports the findings of our 
simulations. 
We utilized an in silico approach to study several hypothetical therapeutic approaches. 
The first agent we examined was a neutralizing anti-TNF antibody, given that elevated TNF 
production is a feature of diabetes (43) and given our ability to simulate many of the 
characteristics of DFU by assuming elevated TNF production. Several FDA-approved anti-TNF 
antibodies are available for the treatment of various inflammatory diseases (86). Our findings 
also suggest that anti-TNF therapy for DFU should be explored. 
Another therapy that we simulated was one in which exogenous, latent TGF-β1 would be 
provided or one that would lead to the activation of endogenous TGF-β1. TGF-β1 modulation 
(either provision of TGF-β1 or its inhibition) has been proposed as a possible therapy for various 
aspects of aberrant wound healing (88). However, treatment with TGF-β1 was not efficacious as 
a DFU therapeutic (89). We reasoned that since latent TGF-β1 has a longer half-life than active 
TGF-β1 (52), it might serve as a better therapeutic agent. Our findings support this hypothesis.  
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The main disadvantage of our model is that it is based on the key mechanisms of 
inflammation and wound healing, but like any simulation does not incorporate all possible 
biological mechanisms that might be operant in the process of inflammation and wound healing. 
Importantly, our ABM does not account for collagen contraction as part of the wound healing 
process, though it is our aim to incorporate this mechanism in later iterations of the model. It 
should be noted that in the ABM framework, it is often difficult to define the direct or indirect 
role of a given variable in the final outcome, and so the more mechanistic rules an ABM contains 
the less likely we are to gain this type of insight. Moreover, the more complex the ABM, the 
greater the computing power necessary to run any single simulation. In this manuscript, we 
strove to balance model realism with tractability, and believe that the overall findings justify this 
compromise. Also, the agent-based model structure contains certain assumptions regarding the 
stochastic nature of some of the processes being modeled, and these assumptions may not 
represent the exact way in which these processes occur in vivo. Another limitation relates to the 
way in which one models the production and clearance of a given agent, as well as the exact 
effects than an agent has on another agent: we have tried to base our assumptions on literature 
data whenever possible, but the literature is incomplete with regards to certain specific 
interactions. Finally, this ABM is calibrated with regards to literature data on skin wound 
healing, but has not been specifically calibrated or validated with prospective data from DFU 
patients, a deficiency we are currently in the process of addressing. 
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APPENDIX A 
We present the numerical method used to solve Eq. 9.  Let  be a 
subdivision of (0,1), such that , the mesh size.  Let  be a given step 
size and let .  Let  denote the numerical approximation of  Equation 9 is 
rewritten as: 
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Using the finite difference approximations of the partial derivatives of x, we obtain the 
following combined implicit/explicit scheme that is second order in space and first order in time 
(note that explicit difference has been used in the denominator and implicit difference in the 
numerator): 
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After rearranging the terms, we obtain: 
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The initial condition is simply  and the boundary conditions yield: jj sx =0
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APPENDIX B 
ABM Rules 
World. The “world” is a square grid, 120 x 120 patches, with origin in the center of the 
grid. X and Y coordinates thus take values in the range of -60 to 60. The tissue region is a circle 
of diameter 55 centered at the origin. 
Time scale. We assumed in the model that 1 unit of simulated time represents 0.069 day, 
or about 1.6 hours. The time resolution of the simulation is in the millisecond range, thus much 
smaller than a time unit. This assumption results in complete healing (defined as return of the 
damage variable to baseline) in the normal scenario by ~30 days. All of the dynamics of cells 
and cytokines are therefore appropriately scaled to give realistic time courses. 
Lifespans and Half-lives. The lifespan was assumed to be 1-3 days for neutrophils, 4-6 
days for macrophages and 5-7 days for fibroblasts. Cytokine half-lives were assumed to be 2-3 
days.  We note the half life of latent TGF- β1 is much larger than the half life of activated TGF- 
β1 (102). Activated fibroblasts proliferate every three days.  
Initialization. We arbitrarily set the total number of resting neutrophils and macrophages 
to 80 each, and the number of resting fibroblasts was set to 30. The location and age of these 
cells was randomly distributed in both blood and tissue. The initial total amount of damage was 
set to M*M, where M is a number set by the user. In our simulations, we set M = 16. This 
damage was randomly distributed inside the disk centered at the origin of the domain and with 
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diameter equal to M. The initial number of platelets p(x,y) was spatially distributed according to 
the formula (100/(1+x^2+y^2)), where (x,y) are grid coordinates. This type of distribution for the 
platelets is crucial for the initialization of the inflammatory process.  The initial values of IL-1β, 
TNF, activated TGF-β1, IL-10, and collagen were set to zero. The initial amount of latent TGF-
β1 was set to 10. 
Activation. ( In this simulation, neutrophils and macrophage are chemoattracted by 
platelets (76) as well as TNF (76)  while fibroblasts are chemoattracted by TGF-β1 (76).  In 
actuality, platelets release several growth factors in addition to TGF-β1, such as PDGF, 
transforming growth factors α (TGF-α), epidermal growth factor (EGF), and insulin-like growth 
factor –I (IGF-I) to activate macrophages and neutrophils (76). However, in our model we do not 
include all of these growth factors, but rather assume, for simplicity, that platelets can activate 
those inflammatory cells in the following way: Macrophages are activated by platelets if the 
number of platelets is greater than (100 /(1+M*M))/(1+P1), where M represents the magnitude 
of the damage, and are activated by TNF if TNF > 0.1 and P1 represents the potency of 
chemoattraction by platelets. At baseline, P1 = P2 = 0. Neutrophils are activated by platelets if 
the number of platelets is greater than (100/(1+M*1.7)*(M*1.7))/(1+P2), where M represents the 
magnitude of the damage, and are activated by TNF if TNF > 0.2. P2 represents the potency of 
chemoattraction of neutrophils by platelets. At baseline, P1 = P2 = 0. For the studies depicted in 
Tables 1 and 2, only the activation portion (not the random walk; see below) is modulated. 
Fibroblasts are activated by TGF-β1 if TGF-β1>0.2 and damage is present.  
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Cell motion: chemoattraction and stochastic motion  
The motion of all agents is due to both chemoattraction and random walk. First, 
neutrophils and macrophage are chemoattracted by platelets (76) as well as TNF (76) while 
fibroblasts are chemoattracted by TGF-β1 (76). Second, every unit time, the direction of cells is 
randomly changed. The final motion is a direct superposition of the random walk and 
chemoattractant-directed motion. For the studies depicted in Tables 4-1 and 4-2, only the 
chemoattractant portion (not the random walk) is modulated. 
 
Mediators 
1. TNF: 
1. Produced by activated macrophages and activated neutrophils. Inhibited by TGF-β1 and IL-
10 and elevated by TNF and IL1-β (77). In the TNF-overproducing simulation, for activated 
macrophages, the dynamics of TNF are calculated by the equation: TNF = TNF + 0.044 * ( 1 
/ ( 0.1 + TGF * 100 + IL-10 / 100 ) ) * ( 1 + TNF + IL1-beta / 10 ) ) ). For activated 
neutrophils, the dynamics of TNF are calculated by the equation: TNF = TNF + 2.2* (1 / (0.1 
+ TGF * 100 + IL-10 / 100) ) * ( 1 + TNF + IL1-beta / 10 ) ) ). In the simulation of TNF-
overproducing with anti-TNF antibody treatment, for activated macrophages, these dynamics 
are calculated by the equation: TNF = TNF + 0.0293 * ( 1 / (0. 1 + TGF * 100 + IL-10 /  
100 ) ) * ( 1 + TNF  + IL1-beta / 10 ) ) ). For activated neutrophils, these dynamics are 
calculated by the equation: TNF = TNF + 1.467* (1 / (0.1 + TGF * 100 + IL-10 / 100 ) ) * ( 1 
+ TNF + IL1-beta / 10 ) ) ). In the simulation of TGF-β1-under-production with anti-TNF 
antibody treatment, for activated macrophages, these dynamics are calculated by the equation: 
TNF = TNF + 0.0067 * ( 1 / (0. 1 + TGF * 100 + IL-10 /  100 ) ) * ( 1 + TNF  + IL1-beta / 
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10 ) ) ). For activated neutrophils, these dynamics are calculated by the equation: TNF = TNF 
+ 0.33* (1 / (0.1 + TGF * 100 + IL-10 / 100 ) ) * ( 1 + TNF + IL1-beta / 10 ) ) ). In the other 
simulations, for activated macrophages, these dynamics are calculated by the equation: TNF 
= TNF + 0.02 * ( 1 / ( 0.1 + TGF * 100 + IL-10 /  100 ) ) * ( 1 + TNF  + IL1-beta / 10 ) ) ). 
For activated neutrophils, these dynamics are calculated by the equation: TNF = TNF +  ( 1 / 
( 0.1 + TGF * 100 + IL-10 /  100 ) ) * ( 1 + TNF  + IL1-beta / 10 ) ) ). 
2.  Biological function: Inhibit the expression of TGF-β1 and IL-10 in activated macrophages. 
Stimulate the expression of TNF and IL-1β in activated macrophages and neutrophils. 
Activate latent TGF-β1, macrophages, and neutrophils (77). 
3. TNF diffuses in the following sense: periodically (every 0.1 unit time) each patch shares 100 
percent of the value of the patch with its 8 neighboring patches. 
2. TGF-β1:  
1. Activated from latent-TGF-β1 by TNF and IL1-β: if TNF>0.2 or IL1-β > 0.2, then TGF 
=TGF + latent-TGF * 0.001; latent-TGF=latent-TGF * 0.999. In the simulations of latent-
TGF treatment, the initial value of latent-TGF equals four. In the other simulations, the initial 
value of latent-TGF equals one. 
2. Produced by activated macrophages and activated fibroblasts. Inhibited by TNF (77).  In the 
simulations of TGF-β1-under-production, for activated macrophages, TGF-β1 dynamics are 
calculated by the equation: TGF=TGF + latent-TGF * 0.03 / (1 + TNF*10). For activated 
fibroblasts, these dynamics are calculated by the equation: TGF=TGF + 0.015 / (1 + TNF/5). 
In the simulations of TGF-β1-under-production with TGF-β1 activation treatment, for 
activated macrophages, TGF-β1 dynamics are calculated by the equation:  TGF=TGF + 
latent-TGF *0.15/ (1 + TNF*10). For activated fibroblasts, these dynamics are calculated by 
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the equation: TGF=TGF + 0.075 / (1 + TNF/5). In the simulations of TNF-overproducing 
with TGF-β1 activation treatment, for activated macrophages, TGF-β1 dynamics are 
calculated by the equation:  TGF=TGF + latent-TGF / (1 + TNF*10). For activated 
fibroblasts, these dynamics are calculated by the equation: TGF=TGF + 0.5 / (1 + TNF/5). In 
the other simulations, for activated macrophages, these dynamics are calculated by the 
equation: TGF=TGF + latent-TGF * 0.2 / (1 + TNF*10). For activated neutrophils, these 
dynamics are calculated by the equation: TGF=TGF + 0.1 / (1 + TNF/5). 
3. Biological function: Inhibit expression of TNF and IL-1β in activated macrophages and 
neutrophils; chemoattract and activate fibroblasts  (77). 
4. TGF-β1 diffuses in the following sense: periodically (every 0.1 s) each patch shares 100 
percent of the value of the patch with its 8 neighboring patches.  
3. IL-1β:  
1.  Produced by activated macrophage and neutrophils. Inhibited by TGF-β1 and IL-10 (78). 
Elevated by TNF and IL1-β. The dynamics of IL-1β are calculated by the equation:  IL1-
beta=IL1-beta + 0.2 / ( 1 + TGF*2+IL-10/100)*(1+TNF+IL1-beta).  
2. Biological function: Simulate TNF and IL-1β expression in activated macrophages and 
neutrophils. Increase TGF-β1 activation (52,76,77). 
3.  IL-1β diffuses in the following sense: periodically (every 0.1 s) each patch shares 100 percent 
of the value of the patch with its 8 neighboring patches 
4.IL-10:  
1.  Produced by activated macrophages. The dynamics of IL-10 are calculated by the equation: 
IL1-10=IL1-10+1. 
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2. Biological function: Inhibit TNF (78,103) and IL-1β (78) expression in activated 
macrophages and neutrophils. 
3. IL-10 diffuses in the following sense: periodically (every 0.1 unit time) each patch shares 100 
percent of the value of the patch with its 8 neighboring patches. 
5. Collagen: 
1. Produced by activated fibroblasts. Inhibited by TNF and elevated by TGF-β1 (46). In 
our model, we also required that the amount of collagen produced not exceed the existing 
amount of damage in the same patch. Collagen dynamics are calculated by the equation: (if 
damage > 2 * total-TGF / (1 + total-TNF), collagen=collagen + 2 * total-TGF / (1 + total-
TNF)) else collagen=collagen + damage). 
2. Biological function: tissue repair (76,77). 
 
Source Terms  
In the simulation, there are damage-dependent sources for resting macrophages and 
resting neutrophils randomly distributed in the tissue and blood. The number of newly created 
neutrophils is a function of the total amount A of damage: 2*(A/1500+1) every 0.5 time units 
until 2.7 days of simulated time are reached. The number of newly created macrophage is a 
function of the total amount A of damage: A/15000+1 every 2 time units until 20 days of 
simulated time are reached. There is also a constant source (two cells per every four time units) 
for resting fibroblasts randomly distributed in the tissue and blood if damage exists.  
Damage:  In addition to initial damage, damage can also be created by TNF if TNF > 
0.25. Damage is healed by collagen (if collagen>0. damage=damage –1.collagen=collagen -1), 
and it also has 0.2% chance for self-healing every time unit. 
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